Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Federal Trade Commission
Accenture
US Department of Justice
Boehringer Ingelheim
Farmers Insurance
Colorcon
Covington
Harvard Business School

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,357,336

« Back to Dashboard

Which drugs does patent 7,357,336 protect, and when does it expire?

Patent 7,357,336 protects VARITHENA and is included in one NDA.

This patent has seventy patent family members in thirty-four countries.
Summary for Patent: 7,357,336
Title:Generation of therapeutic microfoam
Abstract: Improved therapeutic sclerosing microfoams and methods and devices for making them are provided that have advantage in producing a consistent profile injectable foam with minimal input by the physician yet using high volume percentages of blood dispersible gases, thus avoiding use of potentially hazardous amounts of nitrogen.
Inventor(s): Osman; Tariq (London, GB), Shilton-Brown; Sheila Bronwen (Brentwood, GB), Wright; David Dakin Iorwerth (High Wycombe, GB), Harman; Anthony David (Henley-on-Thames, GB), Boorman; Timothy David (Frinton on Sea, GB)
Assignee: BTG International Limited (London, GB)
Application Number:11/171,293
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 7,357,336

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,357,336

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9912356.4May 26, 1999

Non-Orange Book US Patents Family Members for Patent 7,357,336

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,025,290 Generation of therapeutic microfoam ➤ Sign Up
6,572,873 Generation of therapeutic microfoam ➤ Sign Up
8,091,801 Generation of therapeutic microfoam ➤ Sign Up
7,604,185 Generation of therapeutic microfoam ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Dow
Queensland Health
Fish and Richardson
Farmers Insurance
Argus Health
US Army
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.